Insights, Challenges, and Future Directions in Irinogenetics
Authors:
- Federico InnocentiFIFederico Innocenti
- 1 June 2007
- journal article
- review article
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 29 (3) , 265-270
Abstract
Irinotecan is widely used in the treatment of metastatic colorectal cancer and extensive small-cell lung cancer. Its use is limited by severe toxicities such as neutropenia and delayed-type diarrhea. Irinotecan is converted to its active metabolite SN-38. SN-38 is further metabolized to SN-38G by various hepatic and extrahepatic UGT1A isozymes, mainly UGT1A1. Impaired glucuronidation activity of the UGT1A1 enzyme has been linked with elevated levels of SN-38, leading to toxicities. UGT1A1*28 involves an extra TA repeat in the UGT1A1 promoter region and is the variant most frequently contributing to interpatient variability in irinotecan pharmacokinetics and toxicities. This information led to the revision of the irinotecan label by the US Food and Drug Administration. Recently, UGT1A1*6 seems to contribute to the risk of toxicity of irinotecan in Asian patients. The pharmacogenetics of irinotecan (irinogenetics) is one of few promising examples of the application of pharmacogenetics to individualized drug therapy. This review summarizes ongoing studies and unanswered questions on irinogenetics.Keywords
This publication has 42 references indexed in Scilit:
- Activation and antitumor activity of CPT-11 in plasma esterase-deficient miceCancer Chemotherapy and Pharmacology, 2005
- Determination and analysis of single nucleotide polymorphisms and haplotype structure of the human carboxylesterase 2 genePharmacogenetics, 2004
- ?Irinogenetics? and UGT1A: from genotypes to haplotypes*1Clinical Pharmacology & Therapeutics, 2004
- Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small-Cell Lung CancerNew England Journal of Medicine, 2002
- UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicityThe Pharmacogenomics Journal, 2002
- Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2000
- Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphismClinical Pharmacology & Therapeutics, 1999
- Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.Journal of Clinical Investigation, 1998
- Clinical Pharmacokinetics of IrinotecanClinical Pharmacokinetics, 1997
- Molecular aspects of carboxylesterase isoforms in comparison with other esterasesToxicology Letters, 1995